Arrowhead Research | ARWR - Koszty Sprzedaży I Administracji





Koszty Sprzedaży I Administracji Zmiana Data
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Alnylam Pharmaceuticals USD 347.92M 65.41M 2026-06
Anika Therapeutics USD 10.01M 14K 2025-12
Arrowhead Research USD 46.63M 4.88M 2026-06
Heron Therapeutics USD 23.74M 605K 2025-12
Incyte USD 351.73M 23.64M 2026-06
Ionis Pharmaceuticals USD 130.07M 20.92M 2026-06
Ligand Pharmaceuticals USD 29.12M 8.29M 2026-06
Merck USD 2.89B 219M 2026-06
Moderna USD 216M 43M 2026-06
Nektar Therapeutics USD 11.87M 1.7M 2026-03
Novartis USD 3.24B 101M 2026-06
Sarepta Therapeutics USD 107.6M 53.57M 2026-06
TG Therapeutics USD 62.32M 10.82M 2026-06
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
Vertex Pharmaceuticals USD 582.2M 88.5M 2026-06
Xencor USD 77.54M 4.59M 2026-06